Features | Partner Sites | Information | LinkXpress
Sign In
JIB
GLOBETECH PUBLISHING
BioConferenceLive

Root Extract from Traditional Chinese Medicinal Plant Shows Promise as Pain Reliever

By BiotechDaily International staff writers
Posted on 13 Jan 2014
Image: Corydalis yanhusuo plants and isolated rhizomes (inset) (Photo courtesy of Duoclieu, Vietnam).
Image: Corydalis yanhusuo plants and isolated rhizomes (inset) (Photo courtesy of Duoclieu, Vietnam).
A compound isolated from the roots of the traditional Chinese medicinal plant Corydalis yanhusuo has been found to be effective at relieving acute, inflammatory, and neuropathic pains.

Investigators at the University of California, Irvine (USA) and their collaborators at the Dalian Institute of Chemical Physics (China) isolated dehydrocorybulbine (DHCB) from the roots of C. yanhusuo, a flowering herbal plant that grows in Siberia, Northern China, and Japan. Extracts prepared from the roots of this plant have been used for many hundreds of years to alleviate menstrual cramps, chest pain, and abdominal pain.

The investigators tested DHCB in a rodent model. They reported in the January 2, 2014, online edition of the journal Current Biology that it displayed moderate dopamine receptor-antagonist activities. It was effective against inflammatory pain as well as injury-induced neuropathic pain and did not generate the sort of tolerance that develops with continued use of most conventional pain relievers, such as morphine.

Despite the promising results so far obtained, toxicity levels of purified DHCB remain to be established. While purified DHCB is not currently available, it is a component of the C. yanhusuo root or extracts that can be purchased in health stores or online.

“Today the pharmaceutical industry struggles to find new drugs. Yet for centuries people have used herbal remedies to address myriad health conditions, including pain. Our objective was to identify compounds in these herbal remedies that may help us discover new ways to treat health problems,” said senior author Dr. Olivier Civelli, professor of neuropharmacology at the University of California, Irvine. “We are excited that this one shows promise as an effective pharmaceutical. It also shows a different way to understand the pain mechanism.”

Related Links:

University of California, Irvine 
Dalian Institute of Chemical Physics



comments powered by Disqus

Channels

Genomics/Proteomics

view channel
Image: In the liver tissue of obese animals with type II diabetes, unhealthy, fat-filled cells are prolific (small white cells, panel A). After chronic treatment through FGF1 injections, the liver cells successfully lose fat and absorb sugar from the bloodstream (small purple cells, panel B) and more closely resemble cells of normal, non-diabetic animals (Photo courtesy of the Salk Institute for Biological Studies).

Fibroblast Growth Factor 1 Treatment Restores Glucose Control in Mouse Diabetes Model

A "vaccine" based on the metabolic regulator fibroblast growth factor 1 (FGF1) removed the insulin resistance that characterizes type II diabetes and restored the body's natural ability to manage its glucose... Read more

Therapeutics

view channel
Image: This type of electronic pacemaker could become obsolete if induction of biological pacemaker cells by gene therapy proves successful (Photo courtesy of Wikimedia Commons).

Gene Therapy Induces Functional Pacemaker Cells in Pig Heart Failure Model

Cardiovascular disease researchers working with a porcine heart failure model have demonstrated the practicality of using gene therapy to replace implanted electronic pacemakers to regulate heartbeat.... Read more

Lab Technologies

view channel

Precise Ion Irradiation Dosing Method Developed for Cancer Therapy

Scientists are employing nuclear physics principles to provide more effective approaches to radiotherapy treatment for cancer patients. Radiation therapy using heavy ions is best suitable for cancer patients with tumors that are difficult to access, such as in the brain. These particles scarcely damage the penetrated... Read more

Business

view channel

Cancer Immunotherapy Sector Predicted to Surge to USD 9 Billion Across Major Pharma Through 2022

The immunotherapy market will experience substantial growth through 2022, increasing from USD 1.1 billion in 2012 to nearly USD 9 billion in 2022 (corresponding to 23.8% annual growth) in the United Kingdom, United States, France, Germany, Italy, Spain, and Japan, according to recent market research. This notable growth... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.